The emerging technology of massively parallel DNA sequencing has had a major impact on progress in genomics and personalized medicine [1]. Most recently, DNA sequencing of whole exomes (complete coding regions of the human genome) has revealed the genetic basis of many previously-not-localized Mendelian traits [2]. In diseases where the underlying genetic basis is more dilute and complex, old challenges reappear in new clothes [1,3].

Both the promise and the limitations of these new technologies have been evident in the untangling of the polygenic basis of susceptibility to human breast cancer. The identification of single-gene defects in cancer susceptibility syndromes in the 1990s provided a deterministic model of genetic susceptibility to cancer. Discovery and genetic analysis of the hereditary breast and ovarian cancer genes BRCA1 and BRCA2 offered a preview of personalized genomics, improving medical management of a common form of inherited human neoplasia [4,5]. Supporting the idea that new breast cancer genes (often referred to collectively as BRCA3) could be identified, analysis of the genetic variance remaining after BRCA1 and BRCA2 mutations had been excluded suggested that most of the excess genetic risk was concentrated in a small percentage of persons [6]. Yet, genetic linkage studies provided little encouragement for the existence of BRCA3 [7]. While genome-wide association studies (GWAS) uncovered new pathways in cancer biology, the GWAS results identified markers of very modest effect size [8]. The realization that a small proportion of excess genetic risk can be accounted for by common variants has resulted in a return to the study of multiplex breast cancer kindreds and the utilization of massively parallel DNA sequencing to uncover rare, disease-causing mutations in hereditary breast cancer.

The article by Thompson et al., published in this issue of PLOS Genetics [9], along with a similar article published recently in the American Journal of Human Genetics [10], provide a glimpse of the early applications of new sequencing technologies to the search for the “missing heritability” in hereditary breast cancer. In Thompson et al., the authors performed exome sequencing of multiple breast cancer cases from a small number of families (33 persons in 13 families) in whom BRCA1 and BRCA2 mutations had been excluded, and they focused on mutations that are predicted to ablate the function of the gene product, namely, mutations that cause premature termination of translation or that destroy splice-sites. After filtering out the overtly deleterious mutations that are polymorphic in the human population (under the assumption that the risk-causing variation in these breast cancer families should be rare), each sequenced individual harbored on average 35 overtly deleterious mutations. Thus, additional filtering criteria were needed to narrow the field: various strategies are possible, and here the authors focused on genes both hit by mutation in multiple individuals and participating in DNA repair through the homologous recombination pathway, a pathway that repairs double-strand breaks with high fidelity. Previous candidate-gene DNA sequencing studies have implicated homologous recombination in breast cancer susceptibility [11–16], and BRCA1 and BRCA2 themselves are players in this pathway [17]. Remarkably, two families carried overtly deleterious mutations in the Fanconi anemia (FA) gene FANCC and one family carried an overtly deleterious mutation in the Bloom’s syndrome (BS) gene BLM.

FA and BS are rare, autosomal recessive conditions that are characterized by multiple developmental abnormalities (small size and congenital defects of the skin, immune, skeletal, and reproductive systems), striking DNA repair defects and genomic instability in the somatic cells, and enormous predisposition to the development of various cancers (Figure 1) [18,19]. Bi-allelic mutations in FANCC and BLM result in FA and BS, respectively, whereas in Thompson et al. heterozygous mutations in FANCC and BLM were identified in a few breast cancer families studied. The notion that heterozygous mutations in DNA repair genes might predispose carriers to incremental increases in cancer susceptibility is a long-standing and somewhat controversial hypothesis in cancer genetics that has increasingly gained traction. As noted above, heterozygous mutations in FA genes have been associated previously with increased breast cancer risk, and, conversely, bi-allelic mutations in breast cancer-associated genes BRCA2, BRIP1, PALB2, and RAD51C have been identified in persons with FA or FA-like syndromes [20–23]. Although the concept of increased cancer risk conferred by heterozygous mutations now seems unassailable, the evidence for specific associations between FANCC and BLM and breast cancer risk is not yet convincing [24–28]. The challenge of the “heterozygous-mutation” hypothesis is generally one of power. Because the allele frequency of FANCC and BLM mutations in most populations is very low (<0.001), large numbers of individuals are needed to test for differences in the allele frequency between cases and controls. Moreover, heterogeneity in the frequency of mutations across different populations could
complicate interpretation of associations when populations are admixed and as investigators combine results from different populations to increase power. As an example of frequency heterogeneity, FANCC and BLM mutations are more frequent in Ashkenazi Jews (~0.008), where a specific allele is present in most cases of FA and BS [29,30]. Selecting cases with strong family history of cancer is an enrichment strategy that can reduce the numbers of cases needed to find associations [31]. In Thompson et al., the authors sequenced FANCC and BLM, and in total they found FANCC mutations in four probands out of 1,395 BRCA-negative hereditary breast cancer families from Australia and BLM mutations in two probands out of 438 such families. No mutation carriers were found in either gene in 464 controls. No overly deleterious FANC or BLM mutations have been reported in 1,192 completely sequenced persons in the 1000 genomes data [32]. On the other hand, in the NHLBI GO Exome Sequencing Project (http://evs.gs.washington.edu/EVS/), three FANCC and four BLM mutation carriers had been identified in 3,510 exomes. Persons from the 1000 genomes and EVS do not constitute a good control group; thus the authors refrained from calculating p-values, 95% confidence intervals, and effect sizes. Going forward it will be important to compare consecutive breast cancer cases and matched controls drawn from the same population to provide robust data to calculate these important parameters; it may take tens of thousands of cases and controls to quantity them! In addition, we will need to combine studies of hereditary breast cancer cases to increase power and drive segregation analysis, to conduct larger case-control studies in the Ashkenazi Jewish population where the increased frequency of specific alleles increases the power of the study group, and to continue to quantify cancer risk in the relatives of persons with FA and BS.

Thus, rare alleles identified by sequencing of multiplex kindreds pose significant challenges for the estimation of effect sizes in cancer susceptibility. In the end, the critical questions that grip rare alleles are how much increased risk do they confer and do they account for the missing heritability? The resolution of these questions is of paramount importance to genetic epidemiologists studying human populations as well as to clinicians caring for families at risk for hereditary breast cancer.

Acknowledgments

The authors thank the Breast Cancer Research Foundation (http://www.bcrfcure.org), the Fanconi Anemia Research Fund (http://www.fancon.org), and the Bloom’s Syndrome Foundation (http://www.bloomssyndrome.org) for their support.

References

1. Offit K (2011) Personalized medicine: new genomics, old lessons. Hum Genet 130: 3–14.
2. Bamshad MJ, Ng SB, Bigham AW, Tabor HK, Emound MJ, et al. (2011) Exome sequencing as a tool for Mendelian disease gene discovery. Nat Rev Genet 12: 745–755.
3. Kiezun A, Garimella K, Do R, Stitziel NO, Neale BM, et al. (2012) Exome sequencing and the genetic basis of complex traits. Nat Genet 44: 623–630.
4. Robson M, Offit K (2007) Clinical Practice. Management of an inherited predisposition to breast cancer. N Engl J Med 357: 154–62.
5. Kauf ND, Satagopan JM, Robson ME, Scheuer L, Hendley, M et al. (2002) Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 346: 1609–1615.
6. Antoniou AC, Pharoah PD, Mcguigan G, Day NE, Ponder BA, et al. (2001) Evidence for further breast cancer susceptibility genes in addition to BRCA1 and BRCA2 in a population-based study. Genet Epidemiol 21: 1–18.
7. Thompson D, Szabo CI, Mangion J, Oldenburg RA, Odefrey F, et al. (2001) Evaluation of linkage of breast cancer to the putative BRCA3 locus on chromosome 13q21 in 128 multiple case families from the Breast Cancer Linkage Consortium. Proc Natl Acad Sci U S A 98: 827–831.
8. Stadler ZK, Thon P, Robson ME, Weitzel JN, Kauf ND, et al. (2010) Genome-wide association studies of cancer. J Clin Oncol 28(7):4255–67.
9. Thompson ER, Doyle MA, Ryland GL, Rowley SM, Chioog DYY, et al. (2012) Exome sequencing identifies rare deleterious mutations in DNA repair genes FANCC and BLM as potential breast cancer susceptibility alleles. PLoS Genet e1002894. doi:10.1371/journal.p-genet.1002894.
10. Park DJ, Lesueur F, Nguyen-Dumont T, Pertesi M, Odefrey F, et al. (2012) Rare mutations in XRCCC4 increase the risk of breast cancer. Am J Hum Genet 90: 734–739.
11. Meijers-Heijboer H, van den Ouweland A, Klijn J, Waalwijkso M, de Snoo M, et al. (2002) Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet 31: 55–59.
12. Levrin O, Artwool C, Henry RT, Milon KL, Neveling K, et al. (2003) The BRCA1-interacting
helicase BRIP1 is deficient in Fanconi anemia. Nat Genet 37: 931–933.

13. Renwick A, Thompson D, Seal S, Kelly P, Chagtai T, et al. (2006) ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. Nat Genet 38: 873–875.

14. Seal S, Thompson D, Renwick A, Elliott A, Kelly P, et al. (2007) PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet 39: 165–167.

15. Meindl A, Hellebrand H, Wick C, Erven V, Wappenschmidt B, et al. (2010) Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. Nat Genet 42: 410–414.

16. Loveday C, Turnbull C, Ramsay E, Hughes D, Ruark E, et al. (2011) Germline mutations in RAD51D confer susceptibility to ovarian cancer. Nat Genet 43: 879–882.

17. D'Andrea AD (2010) Susceptibility pathways in Fanconi’s anemia and breast cancer. N Engl J Med 362: 1909–1919.

19. German J, Ellis NA (2011) Bloom syndrome. In: Valle D, Beaudet AL, Vogelstein B, Kinzler KW, Antonarkis SE, et al. Scriver’s online metabolic and molecular bases of inherited disease. New York: McGraw Hill. Chapter 30.

20. Howlett NG, Taniguchi T, Olson S, Cox R, Waisfiz Q, et al. (2002) Biallelic inactivation of BRCA2 in Fanconi anemia. Science 297: 606–609.

21. Levinus M, Waisfiz Q, Godthelp BC, de Vries Y, Hussain S, et al. (2005) The DNA helicase BRIP1 is defective in Fanconi anemia complementation group J. Nat Genet 37: 934–935.

22. Reid S, Schindler D, Hanenberg H, Barker K, Hanks S, et al. (2007) Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer. Nat Genet 39: 162–164.

23. Vaz F, Hanenberg H, Schuster B, Barker K, Wiek C, et al. (2010) Mutation of the RAD51C gene in a Fanconi anemia-like disorder. Nat Genet 42: 406–409.

24. Gruber SB, Ellis NA, Rennert G, Offit K, et al. (2002) BLM heterozygosity and the risk of colorectal cancer. Science 297: 2013.

25. Cleary SP, Zhang W, Di Nicola N, Aronson M, Aube J, et al. (2003) Heterozygosity for the BLM(Ash) mutation and cancer risk. Cancer Res 63: 1769–1771.

26. Berwick M, Satagopan JM, Ben-Porat L, Carlson A, Mal K, et al. (2007) Genetic heterogeneity among Fanconi anemia heterozygotes and risk of cancer. Cancer Res 67: 9591–9596.

27. Baris HN, Kedar I, Halpern GJ, Shohat T, Magal N, et al. (2007) Prevalence of breast and colorectal cancer in Ashkenazi Jewish carriers of Fanconi anemia and Bloom syndrome. Isr Med Assoc J 9: 487–490.